Locust Walk examined the global dual-targeting (bi-/multi-specific, fusion protein, etc.) biologics pipeline in immunology & inflammation, from target-pair competitive density to BD deal trends and valuation benchmarks, to assess where the next wave of I&I partnering opportunity lies.
Why biopharma licensing, partnership, and M&A share one path to leverage. Locust Walk’s latest white paper makes the case that licensing, partnerships, and M&A aren’t separate playbooks. They’re one continuum, and the leverage that shapes a deal’s final terms is built (or lost) long before a term sheet appears.
Podcast: Play in new window | Download (Duration: 9:15 — 21.2MB)
Subscribe: Apple Podcasts | Spotify | RSS
During the Asia-focused Episode 37 of Biotalk, Geoff Meyerson, CEO of Locust Walk, reviews key trends from the 2026 Q2
Podcast: Play in new window | Download (Duration: 12:10 — 27.8MB)
Subscribe: Apple Podcasts | Spotify | RSS
During Episode 36 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2026 Q2 Report: Global Trends in Biopharma
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2026 Q2 Report applies the latest data to analyze the current landscape in life sciences deals.
LOCUST WALK NEWS Tearing Off the “China Discount”: How Can Chinese Innovative-Drug BD Deals Sell at Their True Worth? July
Japan is one of the world’s largest pharmaceutical markets—generally regarded as the second-largest globally. Like their US counterparts, Japanese pharmaceutical companies continue to face significant pipeline replenishment needs as global patent cliffs, pricing pressure, and internal R&D productivity challenges intensify.
Locust Walk examined China’s antibody-drug conjugate (ADC) pipeline, from target and payload trends to next-generation modalities and select ASCO 2026 readouts, to assess what it means for oncology drug development and pharma BD.
Locust Walk examined how regional licensing trends are evolving and potential deal strategies to navigate uncertainty amid three converging regulatory shifts: the U.S. Most‑Favored Nation (MFN) Executive Order and proposed GLOBE/GUARD rules, the EU Pharmaceutical Package, and Japan’s NHI pricing reform.
Locust Walk examined the evolving landscape of cross-border transactions involving Chinese biotech and what it truly takes to succeed as a global dealmaker in today’s market.